SOURCE: OmniComm Systems, Inc.

January 09, 2008 10:51 ET

OmniComm Systems, Inc. Experiences Banner Year End Results Delivering Electronic Data Capture (EDC) Services and Support for Clinical Trials

2007 Positions OmniComm as a Major Contender in the Electronic Data Capture Marketplace

FT. LAUDERDALE, FL--(Marketwire - January 9, 2008) - OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that record growth for the company combined with international expansion and a dedicated focus on the company's support services infrastructure have positioned OmniComm as a significant player among the market leaders and a technological leader for integration with EDC related products and services.

"The year 2007 has been a turning point for the company. We have substantially grown our business and have successfully scaled our customer support services to sustain our growth," said Stephen Johnson, Executive Vice President of Business Development, Professional Services and Client Services and Support. "Our integration success stories this year along with the overwhelming success of our CRO Preferred Program™ have allowed us to deliver solutions that really work for the diverse needs of our clients. In 2007, OmniComm has definitely become an EDC market leader."

Milestones for 2007:

--  55 New Business Deals
    --  8 Pharmaceutical Companies
        -  Not including recent win with Valeant Pharmaceuticals
           (contract pending)
    --  13 Biotechnology Companies
        -  Including Top 10 Biotech
    --  10 Medical Device Companies
    --   4 Academic Institutions
    --  19 Contract Research Organizations (CROs)
    --   1 Healthcare Company
--  New locations in Bonn, Germany and Tula, Russia
--  Increased employee headcount from 40 to 77 FTEs
--  Expanded Professional Services Division
--  18 New CRO Preferred Program Partners
--  Integration success stories with Oracle Clinical, SAS, CDISC, HL7,
    PHT's LogPad™ and FastTrack Systems, Inc. TrialSpace Designer™
--  Completion of the first commercial integration of an EDC solution with
    the NCI's Center for Bioinformatics (NCICB) cancer Data Standards
    Repository (caDSR), Sentinel Tool and support for the Theradex Export
    Form
--  Partnership with City of Hope to develop a set of caDSR derived
    standardized case report forms and reporting tools to support National
    Cancer Institute (NCI) reporting requirements

Q4 New Deals 2007:

Pharmaceutical
  --  8 month, Phase II, Psychiatry study extension with 30 sites and
      200 subjects

Biotechnology
  --  15 month, Phase I/II HIV study with 15 sites and 24 subjects
  --  13 month, Phase IIIb cardiovascular study with 10 sites and
      200 subjects
  --  6 month, Phase I/II cardiovascular study with 6 sites and 35 subjects
  --  18 month, Phase IV, HIV study with 2 sites and 115 subjects
  --  23 month, Phase IIIb HIV study with 25 sites and 350 subjects
  --  44 month, Phase III HIV study with 125 sites and 780 subjects
  --  44 month, Phase III HIV study with 125 sites and 780 subjects

Medical Device
  --  48 month, Phase IV cardiovascular study with 30 sites and
      250 subjects
  --  48 month, Phase IV cardiovascular study with 20 sites and
      subjects TBD
  --  Phase II cardiovascular study with 50 sites and 664 subjects
  --  Phase II cardiovascular study with sites and subjects TBD

CRO
  --  3 month, Phase I oncology study with 1 site and 40 subjects
  --  6 month, Phase IIb HIV study with 20 sites and 4000 subjects
  --  18 month, Phase II oncology study with 5 sites and 24 subjects
  --  18 month, Phase II oncology study with 5 sites and 85 subjects
  --  Technology Transfer
  --  Consulting Engagement

Academic
  --  36 month, Phase I Diabetes study with 6 sites and 14 subjects
  --  Phase I Diabetes study with sites and subjects TBD

"OmniComm's 4th quarter is the best quarter that the company has ever experienced," said Cornelis F. Wit, CEO of OmniComm Systems. "The company signed 20 new business deals with a mix of new and existing customers resulting in an outstanding year for OmniComm. We are delighted with our success and look forward to developing strong working relationships with our new customers."

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

  • CONTACT:
    Lizanne Kelley
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    Email Contact